Mechanisms of suppression of cell growth by dual inhibition of ALK and MEK in ALK-positive non-small cell lung cancer

Anaplastic lymphoma kinase (ALK) rearrangement, a key oncogenic driver in a small subset of non-small cell lung cancers, confers sensitivity to ALK tyrosine kinase inhibitors (TKIs). Crizotinib, a first generation ALK-TKI, has superiority to standard chemotherapy with longer progression-free surviva...

Descripción completa

Detalles Bibliográficos
Autores principales: Shrestha, N., Nimick, M., Dass, P., Rosengren, R. J., Ashton, J. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906283/
https://www.ncbi.nlm.nih.gov/pubmed/31827192
http://dx.doi.org/10.1038/s41598-019-55376-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906283/
https://www.ncbi.nlm.nih.gov/pubmed/31827192
http://dx.doi.org/10.1038/s41598-019-55376-4

Ejemplares similares